Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2012

01-04-2012 | Review Article

Management of Pain in the Elderly at the End of Life

Authors: Dr Eric Prommer, Brandy Ficek

Published in: Drugs & Aging | Issue 4/2012

Login to get access

Abstract

Pain is one of the symptoms most frequently encountered in elderly patients at the end of life. The management of pain in the elderly in general has been associated with undertreatment. The geriatric population has been identified as a challenging population with respect to pain management because of issues related to co-morbidities, polypharmacy and cognitive dysfunction. In the geriatric population, the assessment of pain requires measurement of pain intensity, delineation of opioid responsiveness, and clarification of the impact of pain on patients’ psychological, social, spiritual and existential domains. Effective pain management is guided by the World Health Organization (WHO) analgesic stepladder, which categorizes pain intensity according to severity and recommends analgesic agents based on their strength and works effectively in the elderly patient population. Step 1 is reserved for mild pain. Patients in this category are treated with nonopioid analgesics such as acetaminophen, or a nonsteroidal anti-inflammatory, with consideration of an adjuvant analgesic if necessary. Step 2 is reserved for patients experiencing mild to moderate pain who are already taking a nonopioid analgesic, with or without an adjuvant analgesic, but are still experiencing poor analgesic control. Step 2 agents include acetaminophen products containing hydrocodone, oxycodone, codeine and tramadol. Patients with moderate to severe pain require strong analgesics belonging to step 3 of the WHO analgesic stepladder. Step 3 opioids include morphine, hydromorphone, fentanyl, levorphanol, methadone and oxycodone. Familiarity with opioid pharmacokinetics, equi-analgesic dosing and adverse effects is necessary for the safe and effective use of these drugs. The appropriate use of adjuvant analgesics such as antiepileptic drugs, antidepressants and local anaesthetics can enhance the use of opioids, especially in cases where opioid responsiveness may be in question, such as with neuropathic pain. This paper will provide an overview of the analgesic considerations for elderly patients at the end of life.
Literature
1.
Thomas JR, Von Gunten CF. Pain in terminally ill patients: guidelines for pharmacological management. CNS Drugs 2003; 17(9): 621–31CrossRefPubMed
2.
Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20(1): 23–57CrossRefPubMed
3.
Nordgren L, Sörensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs 2003; 2(3): 213–7CrossRefPubMed
4.
Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991; 6(7): 411–22CrossRefPubMed
5.
Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004; 9(5): 571–91CrossRefPubMed
6.
Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61(2): 277–84CrossRefPubMed
7.
Cherny NI, Portenoy RK. Cancer pain: principles of assessment and syndromes. In: Wall PD, Melzack R, editors. Textbook of pain. 4th ed. London: Churchill Livingstone, 1999: 1017–64
8.
9.
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41(3): 273–81CrossRefPubMed
10.
Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005; 9(2): 195–206CrossRefPubMed
11.
Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90(8): 611–6CrossRefPubMed
12.
Strang P, Strang S, Hultborn R, et al. Existential pain: an entity, a provocation, or a challenge? J Pain Symptom Manage 2004; 27(3): 241–50CrossRefPubMed
13.
Overcash J. Symptom management in the geriatric patient. Cancer Control 1998; 5 (3 Suppl. 1): 46–7PubMed
14.
Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003; 106(3): 337–45CrossRefPubMed
15.
Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psycho-som Med 2004; 66(1): 17–22CrossRef
16.
Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Pain 2000; 88: 2164–71
17.
Management of cancer pain: adults. Cancer Pain Guideline Panel. Agency for Health Care Policy and Research. Am Fam Physician 1994; 49(8): 1853–68
18.
Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 1987; 60(5): 1151–8CrossRefPubMed
19.
Graham C, Bond SS, Gerkovich MM, et al. Use of the McGill Pain Questionnaire in the assessment of cancer pain: replicability and consistency. Pain 1980; 8(3): 377–87CrossRefPubMed
20.
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994; 23(2): 129–38PubMed
21.
Ashburn MA, Lipman AG. Management of pain in the cancer patient. Anesth Analg 1993; 76(2): 402–16PubMed
22.
Weiner D, Peterson B, Ladd K, et al. Pain in nursing home residents: an exploration of prevalence, staff perspectives, and practical aspects of measurement. Clin J of Pain 1999; 15(2): 92–101CrossRef
23.
Ezenwa MO, Ameringer S, Ward SE, et al. Racial and ethnic disparities in pain management in the United States. J Nurs Scholarsh 2006; 38(3): 225–33CrossRefPubMed
24.
Gatchel RJ, Peng YB, Peters ML, et al. The biopsychoso-cial approach to chronic pain: scientific advances and future directions. Psychol Bull 2007; 133(4): 581–624CrossRefPubMed
25.
Cutler RB, Fishbain DA, Lu Y, et al. Prediction of pain center treatment outcome for geriatric chronic pain patients. Clin J of Pain 1994; 10(1): 10–7CrossRef
26.
Glock M, Friedman R, Myers P. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia: January 1985 through July 1995: 1147 citations. 2nd ed. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1995
27.
Mystakidou K, Tsilika E, Parpa E, et al. Exploring the relationships between depression, hopelessness, cognitive status, pain, and spirituality in patients with advanced cancer. Arch Psychiatr Nurs 2007; 21(3): 150–61CrossRefPubMed
28.
Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer 1998; 34(5): 627–31CrossRefPubMed
29.
30.
Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002 Dec; 100(3): 213–7CrossRefPubMed
31.
32.
Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 2000; 4(1): 5–15CrossRefPubMed
33.
Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 2001; 21(3): 255–64CrossRefPubMed
34.
Mercadante S, Arcuri E, Ferrera P, et al. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005; 30(5): 485–91CrossRefPubMed
35.
World Health Organization (WHO). Cancer pain relief. 2nd ed. Geneva: WHO, 1996
36.
Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22(1): 185–92CrossRefPubMed
37.
Bellville JW, Forrest WH, Miller E, et al. Influence of age on pain relief from analgesics. JAMA 1971; 217(13): 1835–41CrossRefPubMed
38.
Gloth III FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001; 49(2): 188–99CrossRefPubMed
39.
Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32(1): 271–302CrossRefPubMed
40.
Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to management of cancer pain. Pain 1993; 52(3): 319–24CrossRefPubMed
41.
Herr KA, Garand L. Assessment and measurement of pain in older adults. Clin Geriatr Med 2001; 17(3): 457–viCrossRefPubMed
42.
Lansbury G. Chronic pain management: a qualitative study of elderly people’s preferred coping strategies and barriers to management. Disabil Rehabil 2000; 22(1–2): 2–14CrossRefPubMed
43.
Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. JAMA 1995; 274(23): 1870–3CrossRefPubMed
44.
Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician 2009; 12(1): 269–80PubMed
45.
Larson AM, Polson J, Fontana RJ, et al. Acetaminophen induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42(6): 1364–72CrossRefPubMed
46.
Mercadante S, Casuccio A, Agnello A, et al. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage 1999; 17(5): 351–6CrossRefPubMed
47.
Miranda HF, Silva E, Pinardi G. Synergy between the an-tinociceptive effects of morphine and NSAIDs. Can J Physiol Pharmacol 2004; 82(5): 331–8CrossRefPubMed
48.
Joishy SK, Walsh D. The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J Pain Symptom Manage 1998; 16(5): 334–9CrossRefPubMed
49.
Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 2002; 38(10): 1358–63CrossRefPubMed
50.
Israel FJ, Parker G, Charles M, et al. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2010; 39(3): 548–54CrossRefPubMed
51.
52.
Leppert W, Uczak J. The role of tramadol in cancer pain treatment: a review. Support Care Cancer 2005; 13(1): 5–17CrossRefPubMed
53.
Prommer EE. Tramadol: does it have a role in cancer pain management? J Opioid Manag 2005; 1(3): 131–8PubMed
54.
Pedersen RS, Damkier P, Brøsen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poormetabolizers. Eur J Clin Pharmacol 2006; 62(7): 513–21CrossRefPubMed
55.
Cossmann M, Kohnen C, Langford R, et al. Tolerance and safety of tramadol use: results of international studies and data from drug surveillance [in French]. Drugs 1997; 53Suppl. 2: 50–62CrossRefPubMed
56.
57.
Rodriguez RF, Castillo JM, Castillo MP, et al. Hydro-codone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J of Pain 2008; 24(1): 1–4CrossRef
58.
59.
Rodriguez RF, Castillo JM, del Pilar Castillo M, et al. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study. Clin Ther 2007; 29(4): 581–7CrossRefPubMed
60.
Grond S, Radbruch L, Meuser T, et al. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999; 18(3): 174–9CrossRefPubMed
61.
Omar Tawfik M, Elborolossy K, Nasr F. Tramadol hy-drochloride in the relief of cancer pain: a double blind comparison against sustained release morphine. Pain 1990; 41Suppl. 5: S377CrossRef
62.
Bono AV, Cuffari S. Effectiveness and tolerance of tramadol in cancer pain: a comparative study with respect to buprenorphine. Drugs 1997; 53Suppl. 2: 40–9CrossRefPubMed
63.
Dhaliwal HS, Sloan P, Arkinstall WW, et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. J Pain Symptom Manage 1995; 10(8): 612–23CrossRefPubMed
64.
Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician 2008; 11(2 Suppl.): S133–53PubMed
65.
Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81(3): 429–44CrossRefPubMed
66.
67.
Radbruch L, Trottenberg P, Elsner F, et al. Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. Palliat Med 2011; 25(5): 578–96CrossRefPubMed
68.
Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289–307CrossRefPubMed
69.
Vasisht N, Gever LN, Tagarro I, et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29(10): 647–54CrossRefPubMed
70.
Collins SL, Faura CC, Moore RA, et al. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998; 16(6): 388–402CrossRefPubMed
71.
Stuart-Harris R, Joel SP, McDonald P, et al. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol 2000; 49(3): 207–14CrossRefPubMed
72.
Klepstad P, Kaasa S, Skauge M, et al. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 2000; 44(6): 656–64CrossRefPubMed
73.
De Conno F, Ripamonti C, Fagnoni E, et al. The MER-ITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during ‘titration phase’ in patients with cancer pain. Palliat Med 2008; 22(3): 214–21CrossRefPubMed
74.
Gatti A, Reale C, Occhioni R, et al. Standard therapy with opioids in chronic pain management: ORTIBER study. Clin Drug Investig 2009; 29Suppl. 1: 17–23CrossRefPubMed
75.
National Comprehensive Cancer Network guidelines: adult cancer pain. Version 2.2011. Fort Washington (PA): National Comprehensive Cancer Network, 2011
76.
Radbruch L, Loick G, Schulzeck S, et al. Intravenous titration with morphine for severe cancer pain: report of 28 cases. Clin J of Pain 1999; 15(3): 173–8CrossRef
77.
Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009; 37(4): 632–41CrossRefPubMed
78.
Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001; 22(2): 67–70CrossRefPubMed
79.
Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19(9): 2542–54PubMed
80.
Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358(22): 2332–43CrossRefPubMed
81.
Peuckmann-Post V, Elsner F, Krumm N, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010 Nov 10; (11): CD006788
82.
Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid induced sedation. Pain Med 2003; 4(2): 135–40CrossRefPubMed
83.
Prommer EE. Methadone for cancer pain. Palliative Care: Research and Treatment 2010; 4: 1–10CrossRef
84.
Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005; 19(4): 13–24CrossRefPubMed
85.
Prommer E. Opioid rotation: logical choices for pain that is poorly responsive to morphine. Prog Palliat Care 2009; 17(3): 111–6CrossRef
86.
Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996; 64(2): 293–302CrossRefPubMed
87.
Ehrnrooth E, Grau C, Zachariae R, et al. Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncol 2001; 40(6): 745–50CrossRefPubMed
88.
Mercadante S, Arcuri E, Tirelli W, et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori 2002; 88(3): 239–42PubMed
89.
Kautio AL, Haanpaa M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008; 35(1): 31–9CrossRefPubMed
90.
Preskorn SH, Irwin HA. Toxicity of tricyclic antidepres-sants — kinetics, mechanism, intervention: a review. J Clin Psychiatry 1982; 43(4): 151–6PubMed
91.
Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42(2): 135–44CrossRefPubMed
92.
Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52(5): 547–52CrossRefPubMed
93.
Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy. Neurology 2003; 60(8): 1284–9CrossRefPubMed
94.
Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002; 6(1): 17–24CrossRefPubMed
95.
Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001; 57(9): 1583–8CrossRefPubMed
96.
97.
Heimdal K, Hirschberg H, Slettebø H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. JNeurooncol 1992; 12(2): 141–4
98.
Sorensen PS, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30(1): 22–7CrossRef
99.
Loblaw DA, Wu JSY, Kirkbride P, et al. Pain flare in patients with bone metastases after palliative radiotherapy — nested randomized control trial. Support Care Cancer 2007; 15(4): 451–5CrossRefPubMed
100.
Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002; 6: 61–8CrossRefPubMed
101.
Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22(14): 2909–17CrossRefPubMed
102.
Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000; 60(1): 23–33CrossRefPubMed
103.
Yajnik S, Singh GP, Singh G, et al. Phenytoin as a co-analgesic in cancer pain. J Pain Symptom Manage 1992; 7(4): 209–13CrossRefPubMed
104.
Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies. J Pain Palliat Care Pharmacother 2005; 19(1): 35–43PubMed
105.
Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008; 112(12): 2802–8CrossRefPubMed
106.
Guay DRP. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001; 21(9): 1070–81CrossRefPubMed
107.
Bruera E, Ripamonti C, Brenneis C, et al. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 1992; 7(3): 138–40CrossRefPubMed
108.
Sharma S, Rajagopal MR, Palat G, et al. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 2009; 37(1): 85–93CrossRefPubMed
109.
Sloan P, Basta M, Storey P, et al. Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. Anesth Analg 1999; 89(3): 760–1PubMed
110.
Ripamonti C, Bruera E. Pain and symptom management in palliative care. Cancer Control 1996; 3(3): 204–13PubMed
111.
Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000; 25(5): 459–67PubMed
112.
Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999; 80(3): 533–8CrossRefPubMed
113.
Gammaitoni AR, Davis MW. Pharmacokinetics and tol-erability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002; 36(2): 236–40CrossRefPubMed
114.
Portenoy RK, McCaffery M. Adjuvant analgesics. In: Doyle D, Hanks G, Cherny N, et al., editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993: 187–203
115.
Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001; 429(1–3): 71–8CrossRefPubMed
116.
Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000; 20(4): 246–52CrossRefPubMed
117.
Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol 2008; (182): 313–33
118.
Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 1999; 10(4): 385–90CrossRefPubMed
119.
Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999; 82(2): 111–25CrossRefPubMed
120.
Okon T. Ketamine: an introduction for a pain and palliative medicine physician. Pain Physician 2007; 10(3): 493–500PubMed
121.
Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetra-nabinex in patients with cancer-related pain. Edinburgh: British Pain Society, 2005: 8–11
122.
Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multi-center, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39(2): 167–79CrossRefPubMed
123.
124.
Schreiber S, Getslev V, Backer MM, et al. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav 1999; 64(1): 75–80CrossRefPubMed
125.
Khojainova N, Santiago-Palma J, Kornick C, et al. Olanzapine in the management of cancer pain. J Pain Symptom Manage 2002; 23(4): 346–50CrossRefPubMed
126.
Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60(11): 1524–34CrossRefPubMed
127.
128.
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7(5): 377–87PubMed
129.
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19): 1458–68CrossRefPubMed
130.
Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334(8): 488–93CrossRefPubMed
131.
Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial — the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21(16): 3150–7CrossRefPubMed
132.
Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer Clin Oncol 1991; 27(8): 954–8CrossRef
133.
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16(4): 1574–81PubMed
134.
Prommer EE. Established and potential therapeutic applications of octreotide in palliative care. Support Care Cancer 2008; 16(10): 1117–23CrossRefPubMed
135.
Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000; 18(8): 1780–99PubMed
136.
Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 2000; 7(2): 149–56PubMed
137.
Wong GY, Schroeder DR, Carns PE, et al. Effect of neu-rolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004; 291(9): 1092–9CrossRefPubMed
138.
Bruera E, Brenneis C, Michaud M, et al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988; 62(2): 407–11CrossRefPubMed
139.
Ripamonti C, Zecca E, Brunelli C, et al. Rectal methadone in cancer patients with pain. Ann Oncol 1995; 6(8): 841–3PubMed
140.
Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995; 80(2): 296–302PubMed
141.
De Conno F, Ripamonti C, Saita L, et al. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13(4): 1004–8PubMed
142.
Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44(3): 335–42CrossRefPubMed
143.
Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaes-thesiol Scandinavica 2002; 46(7): 759–70CrossRef
144.
Shelley K, Paech MJ. The clinical applications of intranasal opioids. Curr Drug Deliv 2008; 5(1): 55–8CrossRefPubMed
145.
Reisfield GM, Wilson GR. Rational use of sublingual opioids in palliative medicine. J Palliat Med 2007; 10(2): 465–75CrossRefPubMed
146.
Krajnik M, Zylicz Z, Finlay I, et al. Potential uses of topical opioids in palliative care-report of 6 cases. Pain 1999; 80(1–2): 121–5CrossRefPubMed
Metadata
Title
Management of Pain in the Elderly at the End of Life
Authors
Dr Eric Prommer
Brandy Ficek
Publication date
01-04-2012
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2012
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11599210-000000000-00000

Other articles of this Issue 4/2012

Drugs & Aging 4/2012 Go to the issue

Review Article

Blood-Brain Barrier Permeation and Efflux Exclusion of Anticholinergics Used in the Treatment of Overactive Bladder

Review Article

Combination Pharmacological Therapies for the Management of Benign Prostatic Hyperplasia

Original Research Article

Quality Measures for Medication Continuity in Long-Term Care Facilities, Using a Structured Panel Process

Current Opinion

Aspirin for Primary Prevention of Cardiovascular Events in the Elderly

Original Research Article

The Effect of Cognitive Impairment in the Elderly on the Initial and Long-Term Stability of Warfarin Therapy

Adis Drug Clinical Q&A

Bazedoxifene: A Guide to Its Use in Postmenopausal Osteoporosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits